• S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?

  • Apr 4 2023
  • Length: 24 mins
  • Podcast

S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic? cover art

S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?

Listen for free

View show details

  • Summary

  • Drs Jeffrey Swigris and Ayodeji Adegunsoye discuss fibrosing interstitial lung disease and treatment challenges for individuals with idiopathic pulmonary fibrosis.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982422). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Idiopathic Pulmonary Fibrosis (An Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline https://pubmed.ncbi.nlm.nih.gov/35486072/

    Health-Related Quality of Life and Symptoms in Patients With IPF Treated With Nintedanib: Analyses of Patient-Reported Outcomes From the INPULSIS® Trials https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990488/

    Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Clinical Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089322/
    Show More Show Less
Physical Illness & Disease Hygiene & Healthy Living Science
Show More Show Less

What listeners say about S1 Episode 2: Idiopathic Pulmonary Fibrosis: Who Gets an Antifibrotic?

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.